Company profile
Sales companies
Sales companies Germany
Belgium
Print page
Send page
Save page
Bookmark page
STADA as homepage
International sales activities
Belgium
In Belgium, STADA generated sales growth in the amount of 7% to EUR 134.9 million in2010 (previous year: EUR 125.7 million) – despite state price reductions introduced during the course of the year.
With an increase of 7% to EUR 128.6 million (previous year: EUR 120.2 million), generics continued to have the largest share of local sales in 2010. They had a 95% share of STADA’s sales in Belgium (previous year: 96%). With a market share of approx. 49.1% (previous year: approx. 48.1%), the Belgian STADA subsidiary continued to be the clear local market leader in the generics market there in financial year 2010.1)
The Group generated a sales increase in the amount of 14% to EUR 6.3 million with branded products in Belgium in 2010 (previous year: EUR 5.5 million). Their share of STADA’s sales generated in Belgium amounted to 5% (previous year: 4%).
Operating profitability achieved in Belgium in 2010 was, as expected, at Group average.
In Belgium, STADA recorded a sales plus in the first three quarters of 2011 in the amount of 7% to EUR 105.8 million (1-9/2010: EUR 99.1 million).
With a sales increase of 7% to EUR 100.2 million (1-9/2010: EUR 94.0 million), the Group continued to have the largest share of local sales with generics in the Belgian market. Generics contributed 95% (1-9/2010: 95%) to local STADA sales.
Sales of STADA branded products in Belgium in the first nine months of 2011 increased by 12% to EUR 5.6 million (1-9/2010: EUR 5.1 million). Branded products thereby contributed 5% to sales achieved by STADA in Belgium (1-9/2010: 5%).
For financial year 2011, STADA expects another sales increase in the Belgian market with an operating profitability which will again be at about Group average.
| 1) | STADA estimate based on IMS Health data at ex-factory prices. |
| 1) | Sales below EUR 0.05 million were rounded to EUR 0.0 million. |
